as 3201 has been researched along with Complications of Diabetes Mellitus in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giannoukakis, N | 2 |
| Itogawa, A; Kurono, M; Noguchi, H; Sanjoba, M | 1 |
2 review(s) available for as 3201 and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications.
Topics: Aldehyde Reductase; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Contraindications; Diabetes Complications; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Pyrazines; Spiro Compounds; Structure-Activity Relationship | 2006 |
Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.
Topics: Aldehyde Reductase; Animals; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Enzyme Inhibitors; Humans; Pyrazines; Sorbitol; Spiro Compounds; Treatment Outcome | 2008 |
1 other study(ies) available for as 3201 and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Stability and hydrolysis kinetics of spirosuccinimide type inhibitors of aldose reductase in aqueous solution and retardation of their hydrolysis by the target enzyme.
Topics: Aldehyde Reductase; Diabetes Complications; Drug Stability; Enzyme Inhibitors; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Osmolar Concentration; Pyrazines; Solutions; Spiro Compounds | 2008 |